Daiwa Securities Group
CRNX

Daiwa Securities Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Daiwa Securities Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-282
Closed -$13K – 1243
2025
Q4 		$13K Sell
282
-22
-7% -$979 ﹤0.01% 1170
2025
Q3 		$13K Hold
304
– – ﹤0.01% 1146
2025
Q2 		$9K Hold
304
– – ﹤0.01% 1122
2025
Q1 		$10K Hold
304
– – ﹤0.01% 1094
2024
Q4 		$16K Hold
304
– – ﹤0.01% 1092
2024
Q3 		$16K Buy
304
+31
+11% +$1.6K ﹤0.01% 1109
2024
Q2 		$12K Hold
273
– – ﹤0.01% 1154
2024
Q1 		$13K Hold
273
– – ﹤0.01% 1153
2023
Q4 		$10K Buy
273
+74
+37% +$2.27K ﹤0.01% 1169
2023
Q3 		$6K Hold
199
– – ﹤0.01% 1141
2023
Q2 		$4K Hold
199
– – ﹤0.01% 1193
2023
Q1 		$3K Hold
199
– – ﹤0.01% 1182
2022
Q4 		$4K Hold
199
– – ﹤0.01% 1165
2022
Q3 		$4K Hold
199
– – ﹤0.01% 1172
2022
Q2 		$4K Buy
199
+67
+51% +$1.34K ﹤0.01% 1180
2022
Q1 		$3K Hold
132
– – ﹤0.01% 1214
2021
Q4 		$4K Hold
132
– – ﹤0.01% 1217
2021
Q3 		$3K Buy
132
+70
+113% +$1.46K ﹤0.01% 1209
2021
Q2 		$1K Hold
62
– – ﹤0.01% 1185
2021
Q1 		$1K Hold
62
– – ﹤0.01% 1191
2020
Q4 		$1K Buy
+62
New +$864 ﹤0.01% 1169
2019
Q4 		– Sell
-153
Closed -$2K – 1210
2019
Q3 		$2K Hold
153
– – ﹤0.01% 1125
2019
Q2 		$4K Hold
153
– – ﹤0.01% 1115
2019
Q1 		$3K Sell
153
-67
-30% -$1.65K ﹤0.01% 1105
2018
Q4 		$7K Buy
+220
New +$6.19K ﹤0.01% 1023

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Daiwa Securities Group's CRNX Position: Q1 2026 in Review

Daiwa Securities Group sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 282 shares — an estimated $13K sold.

Daiwa Securities Group first reported a position in CRNX in Q4 2018 and held it in 25 quarters. The position peaked at $16K in Q4 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Daiwa Securities Group reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 282 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $13K.
  • Daiwa Securities Group first reported a position in Crinetics Pharmaceuticals in Q4 2018 and held it in 25 quarters.
  • Daiwa Securities Group's Crinetics Pharmaceuticals position peaked at $16K in Q4 2024.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.